---
run_id: halo-evidence-vs-diagnosis-validation-v7-substrate-workflow-05
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: substrate_workflow
run_number: 5
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 503
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
condition_packet_sha256: 86235e082879e8119f7adb956d7b870675e03f798daf72f80f32353376157508
output_file: model-outputs/substrate_workflow-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `substrate_workflow`, run 5 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 503, on the frozen condition packet.

## Output

I recommend that you advise the CEO to pursue the **targeted evidence pass**.

### Reasoning
The current "upbeat story" presented to the board is a textbook example of the **Halo Effect** (BK-0048-card-001). The recent bump in net revenue retention and faster renewals—driven largely by temporary discounts—has created a general impression of success. This impression is now driving the board and leadership to attribute positive traits to the team (e.g., "customer-obsessed," "disciplined," "clear on market") that were absent six months ago, despite the underlying behaviors remaining the same. The "discipline" being praised is likely just a reflection of the revenue signal, not an independent improvement in operational quality.

Furthermore, the company is confusing execution targets with **Validated Learning** (BK-0007-card-001). The revenue increase is a "vanity metric" because it is tied to six-month discounts rather than empirical evidence that the product solves a core problem. The actual behavioral data—31% front-line retention and abandonment in insurance queues—indicates that the product has not yet achieved the value proposition the sales narrative claims.

Committing to "scaling broadly" (Option 1) or "narrowing the plan" (Option 3) at this moment would be a failure of strategic structure. According to the **Strategy Kernel** (BK-0001-card-001), a real strategy begins with a *diagnosis*—an account of the challenge that picks out the factors that actually matter. Currently, HelioLedger has no valid diagnosis; it has a performance-colored narrative. Scaling broadly would be "coherent action" without a diagnosis, while narrowing to insurance would be a "guiding policy" based on a partial data point (the auditor problem) without testing if that problem is solvable or representative of the broader market.

The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

### The Strongest Reason Against This Recommendation
**The Budget Window.** The board locks the budget in twelve days. A targeted evidence pass—specifically one that pauses discounts and instruments behavior—is a decelerator. It risks killing the current sales momentum and may be perceived by the CEO and Board as "analysis paralysis" or a lack of confidence, potentially leading to a budget cut or a loss of leadership trust in a climate currently intoxicated by the "upbeat story."

### Observable Evidence That Would Change My Mind
I would shift my recommendation to "Scale Broadly" if you could produce data showing that the **front-line reviewer retention rate** (currently 31%) is significantly higher in the cohort of customers who *did not* receive the strategic-feature pitch or the discounts. If organic, un-incentivized users are returning at high rates, it would prove that the value proposition is real and that the revenue bump is a lagging indicator of product-market fit rather than a leading indicator of a pricing trick.
